Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

50.91 +0.79 (+1.58%)
Official Closing Price Updated: 4:10 PM EDT, Sep 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 22,237,514
Open 51.54
Bid (Size) 51.19 (1)
Ask (Size) 51.20 (1)
Prev. Close 50.12
Today's Range 50.71 - 52.16
52wk Range 39.35 - 58.75
Shares Outstanding 2,222,113,553
Dividend Yield 4.48%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer option. Analysts project peak sales of up to $5 billion if approved for... 
Via Benzinga
Exposures Product Safety
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
From Bristol Myers Squibb
Via Business Wire

Performance

YTD
-3.51%
-3.51%
1 Month
+5.80%
+5.80%
3 Month
+22.65%
+22.65%
6 Month
-6.12%
-6.12%
1 Year
-12.06%
-12.06%

More News

Read More
14 Stocks Gain Momentum As August Inflation Comes In Below Expectations
Via Benzinga
Topics Economy
Exposures Interest Rates
NYSE:BMY Shows Potential for a Breakout.
Via Chartmill
What Analysts Are Saying About Bristol-Myers Squibb Stock
Via Benzinga
Current Report: Bristol-Meyers Squibb (BMY)
Via Talk Markets
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades
Via Benzinga
Exposures Product Safety
Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Wall Street On Wait-And-Watch Mode Ahead Of Inflation Data, Bitcoin Holds Above 65.5K: Analyst Says Volatility Ahead Providing Better Entry Point Into Long-term Bull Market
Via Benzinga
Topics Economy
Exposures Interest Rates
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
From Bristol Myers Squibb
Via Business Wire
Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout
Via Investor's Business Daily
Exposures Product Safety
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
Via Benzinga
Exposures Product Safety
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
Via Benzinga
Exposures Product Safety
Analysts Think There's Still Time to Get in on Edgewise, Up 332%
Via MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
Via Benzinga
Exposures Product Safety
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip
Via Investor's Business Daily
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Via Investor's Business Daily
Bristol Myers Squibb Presents Data For Multiple Sclerosis Drug Zeposia, Shows Long-Term Efficacy
Via Benzinga
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
From Bristol Myers Squibb
Via Business Wire
3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade
Via The Motley Fool
Merck Scores Two Key Victories With Keytruda In Women's Cancers
Via Investor's Business Daily
Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma
From Bristol Myers Squibb
Via Business Wire
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.